Industry Trends

North America Intragastric Balloon Market Share was valued at over USD 10.0 million in 2019 and is expected to witness over 17.0% CAGR from 2019 to 2026.

Get more details on this report - Request Free Sample PDF

Increasing pervasiveness of obesity will drive intragastric balloon market growth in the forthcoming period. For instance, as per National Institute of Health (NIH), overweight and obesity is the second leading cause of preventable deaths in the U.S. Growing adoption of unhealthy dietary habits coupled with faltered lifestyle habits such as lack of physical exercise is the major reason for high prevalence of obesity across the globe. Thus, rising obesity incidences will have significant implication on healthcare resources, thereby accelerating industry growth.

Growing awareness regarding obesity as well as associated morbidities will highly impact the demand and adoption of intragastric balloons over the coming years. Many countries are witnessing a significant rise in the national cost of the disease. Hence, many nations are undertaking initiatives to control and manage obesity. Such initiatives will expand the awareness levels regarding obesity management along with various alternatives to control weight gain, including intragastric balloons, thus stimulating market growth over the forecast year.

North America Market Share, By Product

Single intragastric balloon segment accounted for market share of more than 78.0%. Increasing adoption of non-invasive procedures coupled with rising awareness pertaining to the advantages of intragastric balloons should boost demand for single intragastric balloon. Various advantages such as non-surgical procedure, reduced food consumption leading to reduction of weight in short time span is expected to augment the demand for single intragastric balloon over the coming years. 

North America Market Value, By Filling Material

Saline-filled balloon segment is forecasted to progress at more than 16.5% CAGR throughout the projected timeframe. Improved product design coupled with increasing number of obese patients will boost saline filled balloons demand over the forecast period. For instance, the methylene blue dye enables to identify if the balloon is ruptured. Also, it provides a non-invasive and non-pharmacological approach for weight loss, thus leading to segment growth.

North America Market Forecast, By End-use

Hospitals segment accounted for revenue of more than USD 4.5 million in 2019. Increasing usage rate coupled with high funding and availability of highly skilled professionals in hospitals will drive the segment growth. Additionally, growing number of hospitals and increasing technological advancements in the treatment of obesity will spur the hospitals market size during the forecast timeframe.

North America Market Size, By Country

U.S. accounted for the largest market share in the region. The key factor driving the regional growth includes rising prevalence of obesity coupled with high adoption of non-surgical treatments. Awareness about obesity, high healthcare expenditure, increasing prevalence of obesity leading to premature death and presence of developed healthcare infrastructure contributes to the higher market size.

Competitive Market Share

Some of the major industry players involved in North America intragastric balloon market include Allurion Technologies, Apollo Endosurgery, Districlass Medical, Obalon Therapeutics and Reshape Lifesciences among other market players. Companies are undertaking various strategies such as introducing products in new markets, mergers and acquisitions. For instance, in October 2017, Spatz announced its partnership with HUMII clinics in Toronto, Canada for distribution of its flagship product Spatz3 adjustable gastric balloon. This partnership will enable company to expand its geographical outreach.

Industry Background

Although intra gastric balloon were introduced in the 1980s, they were approved by the Department of Health Canada (Health Canada) in 2006 and U.S. FDA in 2015. This was due to presence of severe complications and risks related to intragastric balloon procedure. However, since their introduction, these balloons have undergone various advances in design and safety. For instance, the Spatz Balloon overcomes limitations of earlier balloons such as difficulty in balloon volume adjustment, short-term implantation, and balloon migration to the bowel. Additionally, various companies are currently conducting multicenter clinical trial investigation in the U.S. to explore the relatively untapped U.S. market.